A Breakthrough Alzheimer's Device is Cleared in Europe, Stalled in the US

FARMINGTON HILLS, MI – July 02, 2026 – A potentially transformative technology in the fight against Alzheimer's disease has created a stark divide across the Atlantic. In Europe, patients with mild cognitive impairment now have access to Cerezen, a non-invasive medical device clinically shown to improve memory and regain lost cognitive function. Meanwhile, in the United States, the same device, despite being granted a 'Breakthrough' designation by the FDA, remains unavailable, mired in a regulatory process that is drawing criticism and frustrating patient advocates.

The Michigan-based company behind the device, Renew Bioscience, recently highlighted new peer-reviewed clinical data that validates its therapy as the first to significantly improve cognition and independent functioning in early-stage Alzheimer's patients. This is not a new drug with a complex chemical profile, but a technology that revives a surprisingly simple idea: boosting blood flow to the brain. The resulting regulatory paradox exposes deep questions about how different systems evaluate innovation and what it means for the millions of families desperate for hope.

Beyond Drugs: A Vascular Approach to Brain Health

For decades, the dominant narrative in Alzheimer's research has centered on battling amyloid plaques and tau tangles in the brain, leading to a pipeline of pharmaceutical interventions. Cerezen charts a different course, focusing instead on the vascular system, a contributor to cognitive decline that is gaining increased recognition.

The device uses a non-invasive therapy called External Counterpulsation (ECP), a technology already approved and used in the U.S. for treating cardiac conditions like angina. During a treatment session, which is supervised by a healthcare professional, inflatable cuffs on the patient's legs and hips inflate and deflate in sync with their heartbeat. This process gently but effectively increases the volume of oxygenated blood flowing to all parts of the body, including the brain, essentially giving the vascular system a passive workout.

The clinical results, published in the American Journal of Alzheimer’s Disease & Other Dementias®, are compelling. In a randomized, controlled pivotal study involving 190 subjects with mild cognitive impairment or early Alzheimer's, the treatment group showed statistically significant improvements over the sham group.

“In an FDA approved study, 78% of patients with mild cognitive impairment or early Alzheimer’s improved over their personal baseline after six months of this non-invasive treatment,” said Cerezen’s Chief Medical Advisor, Dr. Jack Juni. “On average, participants gained five points on standard cognitive scales – an improvement roughly equivalent to regaining one to two years' worth of lost function.”

This approach stands in stark contrast to the latest generation of anti-amyloid drugs, which have shown modest benefits in slowing decline but do not reverse it. By focusing on improving cerebral blood flow and endothelial function, the Cerezen therapy aims to restore a healthier brain environment, with cognitive gains as the direct result.

The Regulatory Divide: A Breakthrough in Limbo

The most striking part of Cerezen's story is not its mechanism, but its journey through global regulatory bodies. In October 2025, the device received CE certification under the European Union's stringent new Medical Device Regulation (MDR 2017/745), greenlighting it for the treatment of mild cognitive impairment and mild Alzheimer's disease across Europe.

Yet, in the United States, the device's path has been far more convoluted. The Food and Drug Administration (FDA) granted Renew Bioscience's device Breakthrough Device Designation in 2021, a program intended to expedite the review of technologies that could provide more effective treatment for life-threatening or irreversibly debilitating diseases. The designation acknowledged the device's strong safety profile and its potential to address a massive unmet medical need. Despite this, and subsequent reviews, final clearance for American patients has not been granted.

The disparity is a source of profound frustration for the company. Manoj Bhargava, the founder and CEO, noted that the European review was based on the exact same clinical and technical data submitted to the FDA. "We made every effort to bring this treatment to U.S. patients first," a company representative stated, echoing the CEO's public disappointment. "However, it seems politics is more important than people's lives."

This regulatory divergence means that while European physicians can now offer a validated, non-invasive therapy, American doctors and their patients can only wait. The delay raises critical questions for the industry: Is the FDA's framework, traditionally more oriented toward pharmaceuticals, ill-equipped to efficiently evaluate novel device-based therapies for neurological conditions? And what is the cost of this caution for the more than 7 million Americans currently living with Alzheimer's?

The Economics of Hope: Cost, Access, and Impact

The economic burden of Alzheimer’s is a staggering public health crisis, with annual costs projected to exceed $400 billion in the United States alone. This figure doesn't account for the nearly 12 million unpaid family caregivers who face immense emotional, physical, and financial strain.

Against this backdrop, Cerezen's potential value proposition is enormous. The company cites a study from the University of California San Diego's Herbert Wertheim School of Public Health, which found the treatment to be 'cost-effective' to 'highly cost-effective.' While the specifics of this study are not yet widely published, the general principle is supported by broader research. A 2023 Brown University study, for example, found that several non-drug interventions for dementia saved thousands of dollars in societal costs and improved quality of life compared to usual care.

Crucially, Cerezen's accessibility appears to far exceed that of recent pharmaceutical breakthroughs. The company states that over 70% of Alzheimer's patients would qualify for the therapy. This is a stark contrast to anti-amyloid antibody treatments, which require patients to meet narrow eligibility criteria, undergo expensive PET scans for confirmation, and receive regular intravenous infusions that carry risks of side effects like brain swelling and bleeding.

By offering a non-invasive, drug-free option with a strong safety profile and broad applicability, the technology could fundamentally disrupt the current treatment paradigm, shifting focus toward a more accessible and potentially more sustainable model of long-term care.

The Human Equation: What Regained Function Really Means

Beyond the clinical data and economic models lies the most important impact: the human one. For a person in the early stages of Alzheimer's, regaining 'one to two years' of cognitive function is not an abstract metric. It is the ability to manage one's own finances for another year. It is remembering a grandchild's name. It is maintaining the independence and dignity that the disease relentlessly strips away.

For caregivers, this translates into a profound lightening of their burden. A loved one who is more engaged, more capable, and less confused reduces the constant stress and anxiety that defines the caregiving experience. This improvement in quality of life for both the patient and their family is the ultimate goal of any Alzheimer's intervention.

As Cerezen begins its rollout in Europe, the global Alzheimer's community will be watching closely. The device represents more than just a novel technology; it is a test case for a new approach to treatment, a challenge to the pharmaceutical-first mindset, and a stark illustration of how regulatory pathways can define the borders of hope. For millions of American families, the question remains: how long will they have to wait on the wrong side of that border?